{
  "label": "clinical_signal_03_ep_016",
  "artifact_type": "signal_episode",
  "artifact_id": "sha256:7461c01e99466211fb9d6e768206124e3d40929e155a4d297dfd4186b351d9ab",
  "input_ids": [
    "sha256:b4ba5337b06c8de68ac3315db1a4f6980c5bd48efd529c3914f30297d6afd329",
    "sha256:161174e8025b5c956602ccc4e17b4e677c58230b1b64641f357c400c448b8151"
  ],
  "prompt_id": null,
  "model_config": null,
  "created_at": "2026-02-17T11:54:53.214820",
  "content": "## 2024-06-17 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 204\n- Active: 198\n- Screen Failures Cumulative: 47\n- Withdrawals Cumulative: 6\n\n### Sites\n- Site 01 Enrolled: 20\n- Site 01 Active: 20\n- Site 01 Statin Concomitant: 6\n- Site 02 Enrolled: 15\n- Site 02 Active: 15\n- Site 02 Statin Concomitant: 4\n- Site 03 Enrolled: 19\n- Site 03 Active: 19\n- Site 03 Statin Concomitant: 5\n- Site 04 Enrolled: 13\n- Site 04 Active: 13\n- Site 04 Statin Concomitant: 4\n- Site 05 Enrolled: 17\n- Site 05 Active: 17\n- Site 05 Statin Concomitant: 5\n- Site 06 Enrolled: 12\n- Site 06 Active: 12\n- Site 06 Statin Concomitant: 3\n- Site 07 Enrolled: 22\n- Site 07 Active: 22\n- Site 07 Statin Concomitant: 6\n- Site 08 Enrolled: 15\n- Site 08 Active: 15\n- Site 08 Statin Concomitant: 3\n- Site 09 Enrolled: 17\n- Site 09 Active: 17\n- Site 09 Statin Concomitant: 4\n- Site 10 Enrolled: 13\n- Site 10 Active: 13\n- Site 10 Statin Concomitant: 4\n- Site 11 Enrolled: 19\n- Site 11 Active: 19\n- Site 11 Statin Concomitant: 6\n- Site 12 Enrolled: 15\n- Site 12 Active: 15\n- Site 12 Statin Concomitant: 4\n\n### Lab Panels\n- Statin Subgroup N: 56\n- Statin Subgroup ALT Mean (U/L): 76.2\n- Statin Subgroup ALT Median (U/L): 75.3\n- Statin Subgroup AST Mean (U/L): 59.0\n- Statin Subgroup AST Median (U/L): 57.6\n- Statin Subgroup Bilirubin Mean (mg/dL): 1.02\n- Statin Subgroup Bilirubin Median (mg/dL): 0.99\n- Statin Subgroup ALP Mean (U/L): 76.1\n- Statin Subgroup ALP Median (U/L): 69.4\n- Statin Subgroup Creatinine Mean (mg/dL): 0.99\n- Statin Subgroup Creatinine Median (mg/dL): 0.83\n- Statin Subgroup BUN Mean (mg/dL): 12.2\n- Statin Subgroup BUN Median (mg/dL): 14.8\n- Statin Subgroup WBC Mean (K): 7.0\n- Statin Subgroup WBC Median (K): 6.4\n- Statin Subgroup Platelets Mean (K): 233\n- Statin Subgroup Platelets Median (K): 230\n- Non-Statin Subgroup N: 129\n- Non-Statin Subgroup ALT Mean (U/L): 24.7\n- Non-Statin Subgroup ALT Median (U/L): 22.8\n- Non-Statin Subgroup AST Mean (U/L): 21.9\n- Non-Statin Subgroup AST Median (U/L): 20.9\n- Non-Statin Subgroup Bilirubin Mean (mg/dL): 0.64\n- Non-Statin Subgroup Bilirubin Median (mg/dL): 0.62\n- Non-Statin Subgroup ALP Mean (U/L): 71.7\n- Non-Statin Subgroup ALP Median (U/L): 56.6\n- Non-Statin Subgroup Creatinine Mean (mg/dL): 0.93\n- Non-Statin Subgroup Creatinine Median (mg/dL): 0.89\n- Non-Statin Subgroup BUN Mean (mg/dL): 16.1\n- Non-Statin Subgroup BUN Median (mg/dL): 14.2\n- Non-Statin Subgroup WBC Mean (K): 7.1\n- Non-Statin Subgroup WBC Median (K): 7.4\n- Non-Statin Subgroup Platelets Mean (K): 245\n- Non-Statin Subgroup Platelets Median (K): 230\n\n### Adverse Events\n- AE ID: AE-0055, Description: insomnia, Grade: 1, Relatedness: unlikely related, Resolved: true, Subject Group: statin\n- AE ID: AE-0056, Description: arthralgia, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n- AE ID: AE-0057, Description: jaundice, Grade: 2, Relatedness: probably related, Resolved: true, Subject Group: statin\n- AE ID: AE-0058, Description: nausea, Grade: 2, Relatedness: probably related, Resolved: true, Subject Group: statin\n\n### Concomitant Meds\n- Statin Count: 51\n- ACE Inhibitor Count: 26\n- Metformin Count: 23\n- PPI Count: 19\n- NSAID Count: 12\n- Other Count: 35\n\n### Protocol Deviations\n- PD ID: PD-032, Description: Incorrect lab panel order, repeated, Severity: minor, Site: site_09\n- PD ID: PD-033, Description: Eligibility criterion reassessed, subject confirmed eligible, Severity: minor, Site: site_02\n- PD ID: PD-034, Description: Lab sample mislabeled, corrected same day, Severity: minor, Site: site_03\n\n### Investigator Notes\n- No new safety signals identified this week by local PI\n- Study drug accountability reconciled, no discrepancies\n- Regulatory binder audit: all documents current\n- Site 07 re-assay results: 6/8 specimens confirmed within 5% of original, 2 specimens offset by 12-15%\n\n### Events\n- Central lab courier pickup schedule adjusted for holiday\n- Medical monitor weekly call completed\n\n### Notes\n- Week 16: Site 07 re-assay complete; instrument offset confirmed for 2 of 8 specimens. Statin subgroup ALT approaching 2-3x ULN at multiple sites.",
  "metadata": {
    "episode_id": "clinical_signal_03_ep_016",
    "scope_id": "clinical_signal_03",
    "timestamp": "2024-06-17T10:00:00",
    "phase": "red_herring",
    "signal_density": "medium",
    "episode_type": "signal",
    "layer_name": "signal_episodes",
    "layer_level": 2,
    "build_fingerprint": {
      "scheme": "synix:build:v1",
      "digest": "724335e48952198659b608a79f591f6985cc457d1b0726c271a193e4d218a284",
      "components": {
        "transform": "f5403588af46952374060f29447e5a7639e5b66fc9aef1799b08473882c4bcbc",
        "inputs": "a94b84fbaca9bd62"
      }
    },
    "transform_fingerprint": {
      "scheme": "synix:transform:v2",
      "digest": "f5403588af46952374060f29447e5a7639e5b66fc9aef1799b08473882c4bcbc",
      "components": {
        "transform_id": "cb4ddfa83a38701b",
        "source": "42e76241d396a578",
        "model": "1e2ccf75e96d7ee7"
      }
    }
  }
}